tadalafil has been researched along with monocrotaline in 4 studies
Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (monocrotaline) | Trials (monocrotaline) | Recent Studies (post-2010) (monocrotaline) |
---|---|---|---|---|---|
1,742 | 392 | 1,089 | 1,746 | 3 | 850 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Beardsworth, A; Fujita, K; Kato, M; Nakazawa, T; Sawamura, F | 1 |
Ji, YQ; Liu, CP; Lu, WX; Zeng, Q; Zhang, WH; Zhang, YJ | 1 |
Akers, S; Ambrosini, R; Champion, HC; Glickman, S; Haight, D; Lachant, DJ; Meoli, DF; Staicu, S; White, RJ | 1 |
Dohi, K; Hirayama, M; Ito, H; Kabwe, JC; Ko, H; Maruyama, J; Maruyama, K; Mashimo, T; Mitani, Y; Miyasaka, Y; Nishimura, Y; Ohashi, H; Okamoto, R; Oshita, H; Otsuki, S; Oya, K; Sawada, H; Tsuboya, N; Yodoya, N; Zhang, E | 1 |
4 other study(ies) available for tadalafil and monocrotaline
Article | Year |
---|---|
Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats.
Topics: Animals; Blood Gas Analysis; Carbolines; Cyclic GMP; Disease Progression; Dose-Response Relationship, Drug; Hemodynamics; Hydrogen-Ion Concentration; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Organ Size; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Poisons; Pulmonary Circulation; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Survival; Tadalafil | 2009 |
Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Arterioles; Carbolines; Disease Models, Animal; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Inflammation Mediators; Interleukin-6; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Simvastatin; Tadalafil; Time Factors; Vasodilator Agents | 2012 |
Combination therapy improves vascular volume in female rats with pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Female; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Monocrotaline; Phenylpropionates; Pneumonectomy; Pulmonary Artery; Pyridazines; Rats; Rats, Sprague-Dawley; Tadalafil; Vascular Remodeling; Vasoconstriction; Ventricular Dysfunction, Right; X-Ray Microtomography | 2019 |
CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension.
Topics: Animals; Bone Morphogenetic Protein Receptors, Type II; Clustered Regularly Interspaced Short Palindromic Repeats; Fibrosis; Humans; Hypertension, Pulmonary; Lung; Mice; Monocrotaline; Point Mutation; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Tadalafil | 2022 |